top of page





T2Bacteria and T2Candida Panels run on the automated T2Dx Instrument. They are the first and only FDA-cleared blood tests that identify sepsis-causing pathogens without the wait for blood culture.


Blood tests provide actionable results in just 3 to 5 hours direct from whole blood (EDTA tube). The only other way to identify the species-specific diagnosis requires a blood culture, which can take 1 to 5 days or more.


Today, T2 Biosystems panels are getting patients on the right therapy faster, and the expedited identification of negative test results allows rapid de-escalation of unneeded therapy.


T2DX instrument has a positive clinical impact: Target therapy sooner by reducing the time to species ID, T2Bacteria was shown to identify targeted species of bacteria ~66 hours faster than blood culture.

40% of subjects in the clinical trial may have benefited from the initiation of or a change in therapy 2-days faster with a T2Bacteria result as compared to blood culture alone.


T2 Dx increase clinician confidence in treatment with accurate and reliable results. Impact patient outcomes and reduce length of stay for patients with bloodstream infections.


The T2Dx has demonstrated a 5-day reduction intensive care unit (ICU) stay and has demonstrated a 4.8-day reduction in hospital length of stay.


Improve antimicrobial stewardship having the opportunity to escalate or de-escalate therapy sooner and potential to reduce the overuse of antimicrobials and limit side-effects.

bottom of page